Conexeu Sciences (NASDAQ:CNXU) Issues Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Conexeu Sciences (NASDAQ:CNXU) announced its earnings results on Monday. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.19), Zacks reports.

Conexeu Sciences Stock Performance

Shares of NASDAQ CNXU opened at $4.45 on Wednesday. The company’s 50 day simple moving average is $7.87. The firm has a market cap of $119.08 million and a PE ratio of -40.45. Conexeu Sciences has a 12 month low of $4.19 and a 12 month high of $18.79.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Wall Street Zen raised Conexeu Sciences to a “hold” rating in a report on Saturday, May 30th. Zacks Research upgraded shares of Conexeu Sciences to a “hold” rating in a report on Monday, June 29th. HC Wainwright assumed coverage on shares of Conexeu Sciences in a research report on Monday, June 22nd. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Weiss Ratings assumed coverage on shares of Conexeu Sciences in a research report on Monday, August 17th. They issued a “sell (e-)” rating for the company. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.00.

Insider Buying and Selling at Conexeu Sciences

In other Conexeu Sciences news, Director Lynn Sebastian Purcell bought 202,500 shares of Conexeu Sciences stock in a transaction that occurred on Thursday, June 18th. The stock was purchased at an average price of $0.80 per share, with a total value of $162,000.00. Following the completion of the acquisition, the director directly owned 2,734,240 shares in the company, valued at approximately $2,187,392. This trade represents a 8.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Conexeu Sciences Company Profile

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.